相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Henry Buchwald et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2009)
Effect of laparoscopic Roux-en-Y gastric bypass surgery on hemoglobin A1c levels in diabetic patients: a matched-cohort analysis
Daniel E. Mumme et al.
SURGERY FOR OBESITY AND RELATED DISEASES (2009)
The Why WAIT Program: Improving Clinical Outcomes Through Weight Management in Type 2 Diabetes
Osama Hamdy et al.
CURRENT DIABETES REPORTS (2008)
Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis
Leonard C. Glass et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia
W. A. Scherbaum et al.
DIABETES OBESITY & METABOLISM (2008)
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
J. Rosenstock et al.
DIABETOLOGIA (2008)
Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naive Patients with Type 2 Diabetes: Comparison with Metformin
B. Goeke et al.
HORMONE AND METABOLIC RESEARCH (2008)
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
Anthony H. Barnett et al.
CLINICAL THERAPEUTICS (2007)
Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats
Torsten P. Vahl et al.
ENDOCRINOLOGY (2007)
Rosiglitazone RECORD study: glucose control outcomes at 18 months
P. D. Home et al.
DIABETIC MEDICINE (2007)
Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine:: clinical practice experience from a German subgroup of the PREDICTIVE study
L. F. Meneghini et al.
DIABETES OBESITY & METABOLISM (2007)
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes - A randomized trial
Bernard Zinman et al.
ANNALS OF INTERNAL MEDICINE (2007)
Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes
F. Xavier Pi-Sunyer et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study
S. Dejager et al.
HORMONE AND METABOLIC RESEARCH (2007)
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
John B. Buse et al.
CLINICAL THERAPEUTICS (2007)
Weight changes following the initiation of new anti-hyperglycaemic therapies
G. A. Nichols et al.
DIABETES OBESITY & METABOLISM (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1
Brian D. Green et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Julio Rosenstock et al.
CLINICAL THERAPEUTICS (2006)
Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus
Rajeev Jain et al.
PHARMACOTHERAPY (2006)
Glycaemic control without weight gain in insulin requiring type 2 diabetes: 1-year results of the GAME regimen
H. de Boer et al.
DIABETES OBESITY & METABOLISM (2006)
Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes
K. Kolendorf et al.
DIABETIC MEDICINE (2006)
Potential causes of weight gain in type 1 diabetes mellitus
A. N. Jacob et al.
DIABETES OBESITY & METABOLISM (2006)
Insulin glargine or NPH combined with metformin in type 2 diabetes:: the LANMET study
H Yki-Järvinen et al.
DIABETOLOGIA (2006)
Triple therapy in type 2 diabetes - Insulin glargine or rosiglitazone added to combmiation therapy of sulfonylurea plus metformin in insulin-naive patients
J Rosenstock et al.
DIABETES CARE (2006)
Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study
JA Davidson et al.
DIABETES OBESITY & METABOLISM (2006)
Tissue selectivity of insulin detemir action in vivo
AM Hennige et al.
DIABETOLOGIA (2006)
Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: An 18-week, randomized, open-label study
I Raz et al.
CLINICAL THERAPEUTICS (2005)
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
B Charbonnel et al.
DIABETOLOGIA (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Initiating insulin therapy in type 2 diabetes - A comparison of biphasic and basal insulin analogs
P Raskin et al.
DIABETES CARE (2005)
Biphasic insulin aspart 30: Literature review of adverse events associated with treatment
J Davidson et al.
CLINICAL THERAPEUTICS (2005)
Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial
SR Smith et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2005)
alpha-Glucosidase inhibitors for patients with type 2 diabetes - Results from a cochrane systematic review and meta-analysis
FA van de Laar et al.
DIABETES CARE (2005)
Combination therapy for Type 2 diabetes: repaglinide plus rosiglitazone
P Raskin et al.
DIABETIC MEDICINE (2004)
Prevention of weight gain in type 2 diabetes requiring insulin treatment
H de Boer et al.
DIABETES OBESITY & METABOLISM (2004)
Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double-blind trial
GE Dailey et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone
L Jovanovic et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
Insulin glulisine provides improved glycemic control in patients with type 2 diabetes
G Dailey et al.
DIABETES CARE (2004)
Weight gain during insulin therapy in patients with type 2 diabetes mellitus
S Heller
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients
G Schernthaner et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy
JK Malone et al.
CLINICAL THERAPEUTICS (2004)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial
RE Ratner et al.
DIABETIC MEDICINE (2004)
Adiponectin: A novel adipokine linking adipocytes and vascular function
BJ Goldstein et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients
ML Warren et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
Effects of QD insulin detemir or neutral protamine hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen
D Russell-Jones et al.
CLINICAL THERAPEUTICS (2004)
Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance
LU Monzillo et al.
OBESITY RESEARCH (2003)
Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions
H Schatz et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2003)
Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome
O Hamdy et al.
DIABETES CARE (2003)
Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes -: A randomized, controlled trial
A Fritsche et al.
ANNALS OF INTERNAL MEDICINE (2003)
Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes
T Forst et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2003)
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy
SA Phillips et al.
DIABETES (2003)
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes - A 1-year randomized controlled trial
PA Hollander et al.
DIABETES CARE (2003)
Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents
NJ Furlong et al.
DIABETIC MEDICINE (2003)
Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrolective cohort study
S Martin et al.
DIABETOLOGIA (2003)
Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes
H Sargin et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2003)
A diabetes outcome progression trial (ADOPT)
G Viberti et al.
DIABETES CARE (2002)
Amylin, food intake, and obesity
TK Reda et al.
OBESITY RESEARCH (2002)
Repaglinide versus meiformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy
MJ Furlong et al.
DIABETES CARE (2002)
Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients
A Marre et al.
DIABETES OBESITY & METABOLISM (2002)
The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type I diabetes
MS Fineman et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2002)
Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1
SA Hinke et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year
P Ziccardi et al.
CIRCULATION (2002)
Comparative efficacy of preprandial or postprandial Humalog((R)) Mix75/25 (TM) versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus
M Herz et al.
CLINICAL THERAPEUTICS (2002)
A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump
P Raskin et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2001)
PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein
N Maeda et al.
DIABETES (2001)
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus
S Rosenblatt et al.
CORONARY ARTERY DISEASE (2001)
Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study
MS Kipnes et al.
AMERICAN JOURNAL OF MEDICINE (2001)
Basal insulin therapy in type 2 diabetes - 28-week comparison of insulin glargine (HOE 901) and NPH insulin
J Rosenstock et al.
DIABETES CARE (2001)
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes melitus: A randomized, placebo-controlled study
D Einhorn et al.
CLINICAL THERAPEUTICS (2000)
A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes
P Raskin et al.
DIABETES CARE (2000)
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study
S Aronoff et al.
DIABETES CARE (2000)
Insulin treatment increases skeletal muscle fibre area in patients with diabetes mellitus type 2
T Cederholm et al.
CLINICAL PHYSIOLOGY (2000)
Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 1 diabetes
H Yki-Järvinen et al.
DIABETES CARE (2000)
A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients -: Impact on cardiovascular risk reduction
JA Metz et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes
KV Williams et al.
DIABETES OBESITY & METABOLISM (2000)
Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus - A randomized controlled trial
V Fonseca et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Overweight, obesity, and blood pressure: The effects of modest weight reduction
IL Mertens et al.
OBESITY RESEARCH (2000)
分享论文
